GENEVA, SWITZERLAND--(Marketwire - September 10, 2008) - Addex Pharmaceuticals (SWISS: ADXN) announced clinical data showing that the modified release formulation of ADX10059 has improved commercial potential. Tolerability was dramatically improved while a statistically significant reduction in gastroesophageal reflux was achieved for the second time in clinical trials of this product. The novel formulation is appropriate for longer term twice-daily dosing in Phase IIb GERD and migraine prophylaxis studies scheduled to start in the fourth quarter of 2008. ADX10059 is a first-in-class negative allosteric modulator (NAM) of metabotropic glutamate receptor 5 (mGluR5).